← Back to Search

Procedure

Middle Meningeal Artery Embolization for Subdural Hematoma (EMMA-Can Trial)

N/A
Recruiting
Led By Jai Shankar, MD
Research Sponsored by University of Manitoba
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All patients with subdural hematoma coming to the emergency room or to neurosurgical outpatient clinic
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1month, 3months, 6months
Awards & highlights

EMMA-Can Trial Summary

This trial will assess the safety and effectiveness of MMA-embolization for the treatment of CSDH. The hypothesis is that EMMA will reduce the recurrence rate of SDH with or without concomitant surgical evacuation.

Who is the study for?
The EMMA Can trial is for patients who arrive at the emergency room or neurosurgical clinic with a subdural hematoma, which is bleeding on the brain's surface. Participants must be able to give informed consent and not have allergies to the embolic agent used in treatment.Check my eligibility
What is being tested?
This study tests if blocking blood flow to certain arteries in the brain (middle meningeal artery embolization) can reduce recurrence of subdural hematomas, with or without surgery. It aims to improve patient outcomes by preventing further bleeding.See study design
What are the potential side effects?
Possible side effects may include discomfort at the injection site, allergic reactions to materials used during embolization, minor bruising or bleeding, and rarely more serious complications related to blood vessel blockage.

EMMA-Can Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a subdural hematoma and am seeking emergency or outpatient neurosurgical care.

EMMA-Can Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1month, 3months, 6months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1month, 3months, 6months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Subdural Hematoma recurrence at 3 months
Secondary outcome measures
Mortality
Size

EMMA-Can Trial Design

1Treatment groups
Experimental Treatment
Group I: Embolization of Middle Meningeal Artery for Subdural HematomaExperimental Treatment1 Intervention
All patients with CSDH will undergo embolization of Middle Meningeal artery

Find a Location

Who is running the clinical trial?

University of ManitobaLead Sponsor
595 Previous Clinical Trials
199,426 Total Patients Enrolled
Jai Shankar, MDPrincipal InvestigatorUniversity of Manitoba
3 Previous Clinical Trials
120 Total Patients Enrolled

Media Library

Embolization of the middle meningeal artery (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT04923984 — N/A
Subdural Hematoma Research Study Groups: Embolization of Middle Meningeal Artery for Subdural Hematoma
Subdural Hematoma Clinical Trial 2023: Embolization of the middle meningeal artery Highlights & Side Effects. Trial Name: NCT04923984 — N/A
Embolization of the middle meningeal artery (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04923984 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are eligible to join this research endeavor?

"Affirmative. Clinicaltrials.gov discloses that this experiment, which was established on May 1st 2021, is presently recruiting applicants. The protocol requires 100 patients to be enrolled across a single medical centre."

Answered by AI

Is this research endeavor available to potential participants?

"Affirmative. Per research posted on clinicaltrials.gov, this study is presently enrolling participants; the trial was first published on May 1st 2021 and most recently changed on May 30th 2022. The goal of the trial is to recruit 100 patients at a single site."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)
Jai Shankar 2021. "Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04923984.
~16 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top